文章
醫療新知 > HR+/HER2- 型 晚期乳癌治療新喜訊!

HR+/HER2- 型 晚期乳癌治療新喜訊!

06-02-2023
HR+/HER2- 型 晚期乳癌治療新喜訊!
HR+/HER2- 型 晚期乳癌治療新喜訊!
CDK4/6抑製劑的出現改變了荷爾蒙受體陽性、第二型人類表皮生長因子受體陰性(HR+/HER2-)晚期乳癌治療的格局,並成為標準內分泌聯合治療方案重要元素,但是對於疾病進展快、腫瘤較大、徵狀嚴重的惡性乳癌患者,化療仍是標準的治療選擇。與單藥化療相比,聯合化療具有更高的客觀緩解率(Overall Response Rate, ORR)和更長的無惡化存活期(Progression-Free Survival, PFS),成為這些患者之傳統首選治療方案。

在 2022年12月的世界性乳癌醫學會議SABCS 中,台灣乳癌權威盧彥伸教授公佈第二期臨床試驗RIGHT Choice的結果。RIGHT Choice是首個針對轉移性HR+/HER2- 惡性乳腺癌患者使用聯合化療對比荷爾蒙療法聯合CDK4/6抑制劑的第二期臨床隨機對照試驗。為這類患者帶來化療以外之選擇。

此資訊由諾華製藥(香港)有限公司全力支持
HK2212283919

———
1. O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10 Suppl 3:20-29. doi:10.1634/theoncologist.10-90003-20
2. Lu YS, Mahidin EIBM, et al. Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy. Presented at the 2022 San Antonio Breast Cancer Symposium (SABCS). December 6-10, 2022. Abstract # GS1-10.
3. Yardley DA, Yap YS, et al. Pooled exploratory analysis of survival in patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials. Presented at the European Society of Medical Oncology (ESMO) Congress. September 9-13, 2022. Abstract #205P.
4. Neven P, Fasching PA, et al. Updated overall survival (OS) results from the first-line (1L) population in the Phase III MONALEESA-3 trial of postmenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL). Presented at the European Society for Medical Oncology (ESMO) Breast Cancer Congress. May 4, 2022. Abstract #LBA4, May 4, 2022.
5. Hortobagyi, et al. Overall Survival With Ribociclib Plus Letrozole in Advanced Breast Cancer. N Engl J Med 2022; 386:942-50.
6. Hortobagyi, et al. Overall survival (OS) results from the phase III MONALEESA (ML)-2 trial of postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Presented at the European Society of Medical Oncology (ESMO) Congress, September 16-21, 2021. Abstract #LBA17.
7. Im, SA. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381:307-316.
8. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im S-A, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514–24.
9. Slamon, DJ, et al. Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor 2–negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Presented at the European Society of Medical Oncology (ESMO) Congress, September 29, 2019, Barcelona, Spain. Abstract #LBA7.
10. Slamon D, Neven P, Chia S, et al. Updated overall survival (OS) results from the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 5, 2021. Abstract #1001.
11. Tripathy D, Im S-A, Colleoni M, et al, Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Presented at the San Antonio Breast Cancer Symposium, December 9, 2020. Abstract #PD2-04.
12. Yardley, Denise, A. et. al. Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract #1054.
13. O’Shaughnessy J et al. Overall survival subgroup analysis by metastatic site from the Phase III MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with HR+/HER2− advanced breast cancer. Presented at the San Antonio Breast Cancer Symposium, December 7-10, 2021. Abstract #GS2-01.
14. Novartis Data on File. Novartis Pharmaceuticals Corp: 2021.

城中活動

2024-01-03 3:45 下午 ANIMAL FLOW
2023-12-22 10:30 上午 12月植物染工作坊

疑難排解

會員註冊


或許你會想看
AXA安盛與聯合醫務宣佈策略合作
首次引入中國內地診所門診服務 滿足居住及往返內地港人的醫療需要 為大灣區客戶提供便利優質的跨境醫療服務 AXA […]
醫務衞生局局長盧寵茂教授為養和質子治療中心開幕儀式主禮
(2023 年 12 月 2 日,香港)養和醫療集團(養和)今天舉行養和質子治療中心開幕典禮,標誌著全港首個質 […]
養和質子治療中心盛大開幕 標誌著香港在精準癌症治療的領域上邁出重要的一步
養和質子治療中心盛大開幕 標誌著香港在精準癌症治療的領域上邁出重要的一步 (2023年12月2 日, 香港)養 […]
首項粵港澳大灣區跨境醫療銜接服務合作啟動禮
隨著中國内地與香港正式通關,往來兩地的人次顯著上升, 大眾對跨境優質醫療服務的需求亦日益殷切。保誠保險有限公司 […]
【突破膽管癌治療局限】蔣子樑醫生
膽管是人體內一個細小器官,一旦出現癌變,致命率卻是極高,過往更因缺乏相關藥物,令群醫束手無策。幸而這個劣勢,隨 […]
養和、港大醫學院及香港遺傳性乳癌家族資料庫 聯合推動本港遺傳性乳癌及卵巢癌基因突變的研究
  (2023 年 11 月 15 日,香港)養和醫療集團(養和)、香港大學李嘉誠醫學院 (港大醫學 […]
兌現「5日內開始電療」承諾 香港港安醫院腫瘤中心助力患者把握黃金治療期
【2023年11月10日,香港】香港港安醫院腫瘤中心(Hong Kong Adventist Hospital […]
醫管局指大灣區醫療人才交流計劃內地醫護工作符合期望
醫管局大灣區醫療人才交流計劃實施近半年,10名來自廣東省三甲醫院的醫生,分別於九龍中、九龍西及新界西醫院聯網的 […]
港大醫學院發現癌細胞間互動模式 有望為肝癌治療領域帶來新的突破
香港大學李嘉誠醫學院(港大醫學院)臨床醫學學院病理學系任蕙蘋教授帶領的團隊近期取得重大突破,首次揭示循環小細胞 […]
在家採樣檢測 HPV 助早篩子宮頸癌
子宮頸癌是本港常見癌症及香港女性致命癌症之一,據世衛資料,95%子宮頸癌病例由HPV引發。除了傳統HPV和柏氏 […]
乙型肝炎民間篩查見成果 梁熙籲政府資助市民篩查
民建聯衛生事務發言人、立法會議員梁熙早前與社區組織銀騎士,於去年10月在柴灣漁灣邨舉辦「乙型肝炎社區篩查活動」 […]
香港科技園公司與美國默沙東藥廠攜手為製藥業界創造以數據驅動的新方案
(香港,2023 年 8 月 11 日) – 香港科技園公司(科技園公司)夥拍美國默沙東藥廠(默沙東)舉辦「醫 […]